Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2016

01-04-2016 | Mini Review

T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity

Authors: Roberto González-Amaro, Mónica Marazuela

Published in: Endocrine | Issue 1/2016

Login to get access

Abstract

Different immune cell subsets have a relevant role in the pathogenesis of and tissue damage seen in autoimmune thyroid diseases (AITD), including T regulatory (Treg) lymphocytes and T helper (Th) 17 cells. There are several types of CD4+ Treg cells (Foxp3+, CD69+, Tr1), which are able to prevent the appearance of autoimmune diseases, down regulating the immune response and the inflammatory phenomenon. However, despite their presence in peripheral blood and thyroid tissue from patients with AITD, these cells are apparently unable to put down the autoimmune process. Moreover, many reports indicate the involvement of Th17 cells in chronic inflammatory diseases, including AITD. Nevertheless, it is now evident that these lymphocytes show a remarkable plasticity, giving rise to anti-inflammatory (including Treg lymphocytes) and pro-inflammatory cell subtypes. Nowadays, both Treg and Th17 cells must be considered as key elements in the pathogenesis of AITD as well as plausible potential targets for the next generation of therapeutic options of this condition.
Literature
1.
A. Antonelli, S.M. Ferrari, A. Corrado, A. Di Domenicantonio, P. Fallahi, Autoimmune thyroid disorders. Autoimmun. Rev. 14, 174–180 (2015)CrossRefPubMed
2.
3.
H. Li, T. Wang, The autoimmunity in Graves’ disease. Front. Biosci. 18, 782–787 (2013)CrossRef
4.
Y. Wang, T.J. Smith, Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest. Ophthalmol. Vis. Sci. 55, 1735–1748 (2014)CrossRefPubMedPubMedCentral
5.
L. Bartalena, V. Fatourechi, Extrathyroidal manifestations of Graves’ disease: a 2014 update. J. Endocrinol. Invest. 37, 691–700 (2014)CrossRefPubMed
6.
L.A. Zúñiga, R. Jain, C. Haines, D.J. Cua, Th17 cell development: from the cradle to the grave. Immunol. Rev. 252, 78–88 (2013)CrossRefPubMed
7.
C.R. Grant, R. Liberla, G. Mieli-Vergani, D. Vergani, M.S. Longhi, Regulatory T-cells in autoinmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun. Rev. 14, 105–116 (2015)CrossRefPubMed
8.
A.L. Croxford, P. Kulig, B. Becher, IL-12 and IL-23 in health and disease. Cytokine Growth Factor Rev. 25, 415–421 (2014)CrossRefPubMed
9.
R.K. Gershon, K. Kondo, Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18, 723–737 (1970)PubMedPubMedCentral
10.
S. Hori, T. Takahashi, S. Sakaguchi, Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv. Immunol. 81, 331–371 (2003)CrossRefPubMed
11.
M. Miyara, Y. Ito, S. Sakaguchi, Treg-cell therapies for autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 10, 543–551 (2014)CrossRefPubMed
12.
S. Sakaguchi, D.A. Vignali, A.Y. Rudensky, R.E. Niec, H. Waldmann, The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13, 461–467 (2013)CrossRefPubMed
13.
S. Sakaguchi, K. Wing, Y. Onishi, P. Prieto-Martin, T. Yamaguchi, Regulatory T cells: how do they suppress immune responses? Int. Immunol. 21, 1105–1111 (2009)CrossRefPubMed
14.
Y. Han, Q. Guo, M. Zhang, Z. Chen, X. Cao, CD69+ CD4+ CD25− T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J. Immunol. 182, 111–120 (2009)CrossRefPubMed
15.
M. Vitales-Noyola, L. Doníz-Padilla, C. Álvarez-Quiroga, A. Monsiváis-Urenda, H. Portillo-Salazar, R. González-Amaro, Quantitative and functional analysis of CD69(+) NKG2D(+) T regulatory cells in healthy subjects. Hum. Immunol. 76, 511–518 (2015)CrossRefPubMed
16.
M.G. Roncarolo, S. Gregori, R. Bacchetta, M. Battaglia, Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr. Top. Microbiol. Immunol. 380, 39–68 (2014)PubMed
17.
M. Marazuela, M.A. García-López, N. Figueroa-Vega, H. de la Fuente, B. Alvarado-Sánchez, A. Monsiváis-Urenda, F. Sánchez-Madrid, R. González-Amaro, Regulatory T cells in human autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 91, 3639–3646 (2006)CrossRefPubMed
18.
P. Verginis, H.S. Li, G. Carayanniotis, Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+ CD25+ T cells. J. Immunol. 174, 7433–7439 (2005)CrossRefPubMed
19.
E. Gambineri, T.R. Torgerson, H.D. Ochs, Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of Foxp3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15, 430–435 (2003)CrossRefPubMed
20.
D.J. Kasprowicz, P.S. Smallwood, A.J. Tyznik, S.F. Ziegler, Scurfin (FoxP3) controls T-dependent immune responses in vivo through regulation of CD4+ T cell effector function. J. Immunol. 171, 1216–1223 (2003)CrossRefPubMed
21.
C. Mao, S. Wang, Y. Xiao, J. Xu, Q. Jiang, M. Jin, X. Jiang, H. Guo, G. Ning, Y. Zhang, Impairment of regulatory capacity of CD4+ CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves´ disease. J. Immunol. 186, 4734–4743 (2011)CrossRefPubMed
22.
M. Nakahara, Y. Nagayama, T. Ichikawa, L. Yu, G.S. Eisenbarth, N. Abiru, The effect of regulatory T-cell depletion on the spectrum of organ-specific autoimmune diseases in nonobese diabetic mice at different ages. Autoimmunity 44, 504–510 (2011)CrossRefPubMed
23.
D. Pan, Y.H. Shin, G. Gopalakrishnan, J. Hennessey, L.J. De Groot, Regulatory T cells in Graves’ disease. Clin. Endocrinol. 71, 587–593 (2009)CrossRef
24.
P. Verginis, H.S. Li, G. Carayanniotis, Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+ CD25+ T cells. J. Immunol. 174, 7433–7439 (2005)CrossRefPubMed
25.
A.B. Glick, A. Wodzinski, P. Fu, A.D. Levine, D.N. Wald, Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid 23, 871–878 (2013)CrossRefPubMedPubMedCentral
26.
A. Bossowski, M. Moniuszko, M. Dabrowska, B. Sawicka, M. Rusak, M. Jeznach, J. Wójtowicz, A. Bodzenta-Lukaszyk, A. Bossowska, Lower proportions of CD4+ CD25high and CD4+ Foxp3+, but not CD4+ CD25+ CD127lowFoxp3+ T cell levels in children with autoimmune thyroid diseases. Autoimmune 46, 222–230 (2013)CrossRef
27.
A. Rodríguez-Muñoz, M. Vitales-Noyola, A. Ramos-Levi, A. Serrano-Somavilla, R. González-Amaro, M. Marazuela, Levels of regulatory T cells CD69+ NKG2D+ IL-10+ are increased in patients with autoimmune thyroid disorders. Endocrine (2015). doi:10.​1007/​s12020-015-0662-2 PubMed
28.
29.
F. Annunziato, L. Cosmi, F. Liotta, E. Maggi, S. Romagnani, Human T helper type 1 dichotomy: origin, phenotype and biological activities. Immunology 144, 343–351 (2014)
30.
Y.K. Lee, R. Mukasa, R.D. Hatton, C.T. Weaver, Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 21, 274–280 (2009)CrossRefPubMed
31.
G. Beriou, C.M. Costantino, C.W. Ashley, L. Yang, V.K. Kuchroo, C. Baecher-Allan, D.A. Hafler, IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113, 4240–4249 (2009)CrossRefPubMedPubMedCentral
32.
H.J. Koenen, R.L. Smeets, P.M. Vink, E. van Rijssen, A.M. Boots, I. Joosten, Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340–2352 (2008)CrossRefPubMed
33.
H.J. Bovenschen, P.C. van de Kerkhof, P.E. van Erp, R. Woestenenk, I. Joosten, H.J. Koenen, Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J. Invest. Dermatol. 131, 1853–1860 (2011)CrossRefPubMed
34.
S.A. McClymont, A.L. Putnam, M.R. Lee, J.H. Esensten, W. Liu, M.A. Hulme, U. Hoffmüller, U. Baron, S. Olek, J.A. Bluestone, T.M. Brusko, Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918–3926 (2011)CrossRefPubMedPubMedCentral
35.
36.
R. Du, H. Zhao, F. Yan, H. Li, IL-17+ Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J. Leukoc. Biol. 96, 39–48 (2014)CrossRefPubMed
37.
L. Shi, M. Bi, R. Yang, J. Zhou, S. Zhao, C. Fan, Z. Shan, Y. Li, W. Teng, Defective expression of regulatory B cells in iodine-induced autoimmune thyroiditis in non-obese diabetic H-2(h4) mice. J. Endocrinol. Invest. 37, 43–50 (2014)CrossRefPubMed
38.
T.R. Mosmann, H. Cherwinski, M.W. Bond, M.A. Giedlin, R.L. Coffman, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokines activities and secreted proteins. J. Immunol. 136, 2348–2357 (1986)PubMed
39.
N. Schmitt, H. Ueno, Regulation of human helper T cell subset differentiation by cytokines. Curr. Opin. Immunol. 34, 130–136 (2015)CrossRefPubMed
40.
S. Aggarwal, N. Ghilardi, M.H. Xie, F.J. de Sauvage, A.L. Gurney, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003)CrossRefPubMed
41.
E. Rouvier, M.F. Luciani, M.G. Mattei, F. Denizot, P. Golstein, CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150, 5445–5456 (1993)PubMed
42.
Z. Yao, S.L. Painter, W.C. Fanslow, D. Ulrich, B.M. Macduff, M.K. Spriggs, R.J. Armitage, Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483–5486 (1995)PubMed
43.
X. Song, H. Gao, Y. Qian, Th17 differentiation and their pro-inflammation function. Adv. Exp. Med. Biol. 841, 99–151 (2014)CrossRefPubMed
44.
C.L. Langrish, Y. Chen, W.M. Blumenschein, J. Mattson, B. Basham, J.D. Sedgwick, T. McClanahan, R.A. Kastelein, D.J. Cua, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005)CrossRefPubMedPubMedCentral
45.
K. Ghoreschi, A. Laurence, X.P. Yang, C.M. Tato, M.J. McGeachy, J. Konkel, H.L. Ramos, L. Wei, T. Davidson, N. Bouladoux, J. Grainger, Q. Chen, Y. Kanno, W.T. Watford, H.W. Sun, G. Eberl, E. Schevach, Y. Belkaid, D.J. Cua, W. Chen, O´Shea, J.J.: Generation of pathogenic Th17 cells in the absence of TGF-β signaling. Nature 467, 967–971 (2010)CrossRefPubMedPubMedCentral
46.
K. Ghoreschi, A. Laurence, X.P. Yang, K. Hirahara, J.J. O’Shea, T helper 17 cell heterogeneity and pathogenicity in autoinmune disease. Trends Immunol. 32, 395–401 (2011)CrossRefPubMedPubMedCentral
47.
Y. Lee, A. Awasthi, N. Yosef, F.J. Quintana, S. Xiao, A. Peters, C. Wu, M. Kleinewietfeld, S. Kunder, D. Hafler, R.A. Sobel, A. Regev, V.K. Kuchroo, Induction and molecular signature of pathogenic Th17 cells. Nat. Immunol. 13, 991–999 (2012)CrossRefPubMedPubMedCentral
48.
S.A. Basdeo, B. Moran, D. Cluxton, M. Canavan, J. McCormick, M. Connolly, C. Orr, K.H.G. Mills, D.J. Veale, U. Fearon, J.M. Fletcher, Polyfunctional, pathogenic CD161+ Th17 cells lineage cells are resistant to regulatory T cell-mediated suppression in the context of autoimmunity. J. Immunol. 195, 528–540 (2015)CrossRefPubMed
49.
R. Ramesh, L. Kozhaya, K. McKevitt, I.M. Djuretic, T.J. Carlson, M.A. Quintero, J.L. McCauley, M.T. Abreu, D. Unutmaz, M.S. Sundrud, Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211, 89–114 (2014)CrossRefPubMedPubMedCentral
50.
T. Feng, A.T. Cao, C.T. Weaver, C.O. Elson, Y. Cong, Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis. Gastroenterology 140, 2031–2043 (2011)CrossRefPubMedPubMedCentral
51.
M.A. Kluger, M.C. Meyer, A. Nosko, B. Goerke, M. Luig, C. Wegscheid, G. Tiegs, R.A. Stahl, U. Panzer, O.M. Steinmetz, RORγt+ Foxp3+ cells are an independent bifunctional regulatory T cell lineage and mediate crescentic GN. J. Am. Soc. Nephrol. (2015). doi:10.​1681/​ASN.​2014090880
52.
53.
I. Horie, N. Abiru, Y. Nagayama, G. Kuriya, O. Saitoh, T. Ichikawa, Y. Iwakura, K. Eguchi, T helper type 17 immune response plays an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese diabetic-H2h4 mice. Endocrinology 150, 5135–5142 (2009)CrossRefPubMed
54.
F. Hayashi, M. Watanabe, T. Nanba, N. Inoue, T. Akamizu, Y. Iwatani, Association of the -31C/T functional polymorphism in the interleukine-1β gene with the intractability of Graves’ disease and the proportion of T helper type 17 cells. Clin. Exp. Immunol. 158, 281–286 (2009)CrossRefPubMedPubMedCentral
55.
T. Nanba, M. Watanabe, N. Inoue, Y. Iwatani, Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid 19, 495–501 (2009)CrossRefPubMed
56.
N. Figueroa-Vega, M.A. Pérez, I. Benedicto, F. Sánchez-Madrid, R. González-Amaro, M. Marazuela, Increased circulating pro-inflammatory cytokine and Th17 lymphocytes in Hashimoto´s thyroiditis. J. Clin. Endocrinol. Metab. 95, 953–962 (2010)CrossRefPubMed
57.
Q. Qin, P. Liu, L. Liu, R. Wang, N. Yan, J. Yang, X. Wang, M. Pandey, J. Zhang, The increased but non-predominant expression of Th17- and Th1-specific cytokines in Hashimoto´s thyroiditis but not in Graves´ disease. Braz. J. Med. Biol. Res. 45, 1202–1208 (2012)CrossRefPubMedPubMedCentral
58.
D. Peng, B. Xu, Y. Wang, H. Guo, Y. Jiang, A high frequency of circulating Th22 and Th17 cells in patients with new onset Graves’ disease. PloS One 8, e68446 (2013)CrossRefPubMedPubMedCentral
59.
D. Li, W. Cai, R. Gu, Y. Zhang, H. Zhang, K. Tang, P. Xu, F. Katirai, W. Shi, L. Wang, T. Huang, B. Huang, Th17 plays a role in the pathogenesis of Hashimoto’s thyroiditis in patients. Clin. Immunol. 149, 411–420 (2013)CrossRefPubMed
60.
B. Kristensen, L. Hegedüs, H.O. Madsen, T.J. Smith, C.H. Nielsen, Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto´s thyroiditis. Clin. Exp. Immunol. 180, 58–69 (2015)CrossRefPubMed
61.
H. Guo, D. Peng, Y. Wang, B.C. Xu, J.S. Ni, W. Meng, Y.F. Jiang, A higher frequency of circulating IL-22+ CD4+ T cells in chinese patients with newly diagnosed Hashimoto’s thyroiditis. PloS One 9, e84545 (2014)CrossRefPubMedPubMedCentral
62.
H. Xue, X. Yu, L. Ma, S. Song, Y. Li, L. Zhang, T. Yang, H. Liu, The possible role of CD4+ CD25highFoxp3+/CD4+ IL-17A+ cell imbalance in the autoimmunity of patients with Hashimoto thyroiditis. Endocrine (2015). doi:10.​1007/​s12020-015-0569-y PubMed
63.
S. Wang, S.E. Baidoo, Y. Liu, C. Zhu, J. Tian, J. Ma, J. Tong, J. Chen, X. Tang, H. Xu, L. Lu, T cell-derived leptin contributes to increased frequency oh T helper type 17 cells in female patients with Hashimoto’s thyroiditis. Clin. Exp. Immunol. 171, 63–68 (2012)CrossRefPubMedCentral
64.
Y. Liu, X. Tang, J. Tian, C. Zhu, H. Peng, K. Rui, Y. Wang, C. Mao, J. Ma, L. Lu, H. Xu, S. Wang, Th17/Treg cells imbalance and GITRL profile in patients with Hashimoto´s thyroiditis. Int. J. Mol. Sci. 15, 21674–21686 (2014)CrossRefPubMedPubMedCentral
65.
S. Leskela, A. Serrano, H. de la Fuente, A. Rodríguez-Muñoz, A. Ramos-Levi, M. Sampedro-Núñez, F. Sánchez-Madrid, R. González-Amaro, M. Marazuela, Graves’ disease is associated with defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells. PLoS One 16, e0123938 (2015)CrossRef
66.
J.R. Li, F.Y. Hong, J.Y. Zeng, G.L. Huang, Functional interleukin-17 receptor A are present in the thyroid gland in intractable Graves’ disease. Cell. Immunol. 281, 85–90 (2013)CrossRefPubMed
67.
R.H. Song, Z.Y. Yu, Q. Qin, X. Wang, F.S. Muhali, L.F. Shi, W.J. Jiang, L. Xiao, D.F. Li, J.A. Zhang, Different levels of circulating Th22 cell and its related molecules in Graves’ disease and Hashimoto’s thyroiditis. Int. J. Clin. Exp. Pathol. 7, 4024–4031 (2014)PubMedPubMedCentral
68.
X. Bai, J. Sun, W. Wang, Z. Shan, H. Zheng, Y. Zhao, M. Gong, W. Teng, Increased differentiation of Th22 cells in Hashimoto’s thyroiditis. Endocr. J. 61, 1181–1190 (2014)CrossRefPubMed
69.
R.M. Ruggeri, P. Minciullo, S. Saitta, S. Giovanazzo, R. Certo, A. Campennì, F. Trimarchi, S. Gangemi, S. Benvenga, Serum interleukin-22 (IL-22) is increased in the early stage of Hashimoto’s thyroiditis compared to non-autoimmune thyroid disease and healthy controls. Hormones 13, 338–344 (2014)PubMed
70.
R.M. Ruggeri, S. Saitta, M. Cristani, S. Giovanazzo, V. Tigano, F. Trimarchi, S. Benvenga, S. Gangemi, Serum interleukin-23 (IL-23) is increased in Hashimoto´s thyroiditis. Endocr. J. 61, 359–363 (2014)CrossRefPubMed
71.
L. Guan, X. Wang, S. Meng, L. Shi, W. Jiang, L. Xiao, X. Shi, J. Xu, J. Zhang, Increased IL-21/IL-22R expression and its proinflammatory effects in autoimmune thyroid disease. Cytokine 72, 160–165 (2015)CrossRefPubMed
72.
S.J. Shan, R.S. Douglas, The pathophysiology of thyroid eye disease. J. Neuroophthalmol. 34, 177–185 (2014)CrossRefPubMed
73.
H. Wei, M. Guan, Y. Qin, C. Xie, X. Fu, F. Gao, Y. Xue, Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves’ ophthalmopathy. Endocr. J. 61, 1087–1089 (2014)CrossRefPubMed
74.
S.E. Kim, J.S. Yoon, K.H. Kim, S.Y. Lee, Increased serum interleukin-17 in Graves’ ophthalmopathy. Graefes Arch. Clin. Exp. Ophthalmol. 250, 1521–1526 (2012)CrossRefPubMed
75.
A.K. Huber, E.M. Jacobson, K. Jazdzewski, E.S. Concepcion, Y. Tomer, Interleukin (IL)-23 receptor is a major susceptibility gene for Graves’ ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J. Clin. Endocrinol. Metab. 93, 1077–1081 (2008)CrossRefPubMedPubMedCentral
76.
L. Zheng, P. Ye, C. Liu, The role of the IL-23/IL-17 axis in the pathogenesis of Graves’ disease. Endocr. J. 60, 591–597 (2013)CrossRefPubMed
77.
F. Rajaii, A.N. McCoy, T.J. Smith, Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. Expert. Rev. Ophthalmol. 9, 227–234 (2014)CrossRefPubMedPubMedCentral
78.
D. Cao, R. van Vollenhoven, L. Klareskog, C. Trollmo, V. Malmstrom, CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 6, R335–R346 (2004)CrossRefPubMedPubMedCentral
79.
M.R. Ehrenstein, J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, C. Mauri, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200, 277–285 (2004)CrossRefPubMedPubMedCentral
80.
J. Haas, A. Hug, A. Viehover, B. Fritzsching, C.S. Falk, A. Filser, T. Vetter, L. Milkova, M. Korporal, B. Fritz, B. Storch-Hagenlocher, P.H. Krammer, E. Suri-Payer, B. Wildemann, Reduced suppressive effect of CD4+ CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35, 3343–3352 (2005)CrossRefPubMed
81.
U. Feger, C. Luther, S. Poeschel, A. Melms, E. Tolosa, H. Wiendl, Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin. Exp. Immunol. 147, 412–418 (2007)CrossRefPubMedPubMedCentral
82.
J. Maul, C. Loddenkemper, P. Mundt, E. Berg, T. Giese, A. Stallmach, M. Zeitz, R. Duchmann, Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128, 1868–1878 (2005)CrossRefPubMed
83.
H. Sugiyama, R. Gyulai, E. Toichi, E. Garaczi, S. Shimada, S.R. Stevens, T.S. McCormick, K.D. Cooper, Dysfunctional blood and target tissue CD4+ CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174, 164–173 (2005)CrossRefPubMedPubMedCentral
84.
H.J. Bovenschen, P.C. van de Kerkhof, P.E. van Erp, R. Woestenenk, I. Joosten, H.J. Koenen, Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17Aproducing cells and are found in lesional skin. J. Invest. Dermatol. 131, 1853–1860 (2011)CrossRefPubMed
85.
T.M. Brusko, C.H. Wasserfall, M.J. Clare-Salzler, D.A. Schatz, M.A. Atkinson, Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54, 1407–1414 (2005)CrossRefPubMed
86.
J.M. Lawson, J. Tremble, C. Dayan, H. Beyan, R.D. Leslie, M. Peakman, T.I. Tree, Increased resistance to CD4+ CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353–359 (2008)CrossRefPubMedPubMedCentral
87.
B. Alvarado-Sánchez, B. Hernández-Castro, D. Portales-Pérez, L. Baranda, E. Layseca-Espinosa, C. Abud-Mendoza, A.C. Cubillas-Tejeda, R. González-Amaro, Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 27, 110–118 (2006)CrossRefPubMed
88.
J.C. Crispin, A. Martínez, J. Alcocer-Varela, Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 21, 273–276 (2003)CrossRefPubMed
89.
A. Alunno, M. Manetti, S. Caterbi, L. Ibba-Manneschi, O. Bistoni, E. Bartoloni, V. Valentini, R. Terenzi, R. Gerli, Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory th17 cells and therapeutic implications. Mediat. Inflamm. (2015). doi:10.​1155/​2015/​751793
90.
S. Alvermann, C. Hennig, O. Stüve, H. Wiendl, M. Stangel, Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. JAMA Neurol. 71, 905–912 (2014)CrossRefPubMed
91.
J.S. Tzartos, M.A. Friese, M.J. Craner, J. Palace, J. Newcombe, M.M. Esiri, L. Fugger, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008)CrossRefPubMedPubMedCentral
92.
C.S. Catana, I. Berindan Neagoe, V. Cozma, C. Magdas, F. Tabaran, D.L. Dumitrascu, Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 21, 5823–5830 (2015)PubMedPubMedCentral
93.
94.
L. Reinert-Hartwall, J. Honkanen, H.M. Salo, J.K. Nieminen, K. Luopajärvi, T. Härkönen, R. Veijola, O. Simell, J. Ilonen, A. Peet, V. Tillmann, M. Knip, O. Vaarala, DIABIMMUNE Study Group, Th1/Th17 plasticity is a marker of advanced β cell autoimmunity and impaired glucose tolerance in humans. J. Immunol. 194, 68–75 (2015)CrossRefPubMedPubMedCentral
95.
M.S. Maddur, P. Miossec, S.V. Kaveri, J. Bayry, Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am. J. Pathol. 181, 8–18 (2012)CrossRefPubMed
Metadata
Title
T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity
Authors
Roberto González-Amaro
Mónica Marazuela
Publication date
01-04-2016
Publisher
Springer US
Published in
Endocrine / Issue 1/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0759-7

Other articles of this Issue 1/2016

Endocrine 1/2016 Go to the issue

Original Article

Type of fish consumed and thyroid autoimmunity in pregnancy and postpartum

Endocrine Imaging

Hyperosmolar coma in a patient with hypothalamic Langerhans cell histiocytosis

Original Article

Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score

Original Article

Increased serum gamma-glutamyltransferase levels are associated with ventricular instability in type 2 diabetes

Editorial

Skeletal health in adult growth hormone deficiency

Original Article

Rescue in vitro maturation (IVM) of immature oocytes in stimulated cycles in women with low functional ovarian reserve (LFOR)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits